# OnCo record low-grade-serous-ovarian-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/low-grade-serous-ovarian-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "low-grade-serous-ovarian-cancer" ;
  schema:name "Low-grade serous ovarian cancer"@en ;
  schema:alternateName "LGSOC"@en, "Low-grade serous carcinoma"@en ;
  schema:description "Low-grade serous cancer is the slow-growing, chemotherapy-resistant cousin of the common ovarian cancer. Surgery and hormone therapy are its mainstays, and MEK inhibitors, alone or combined with a FAK inhibitor, are the first drugs shown to shrink it reliably."@en ;
  schema:url <https://onco.cc/cancers/low-grade-serous-ovarian-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/clear-cell-ovarian-cancer/>, <https://onco.cc/cancers/mucinous-ovarian-cancer/>, <https://onco.cc/cancers/granulosa-cell-tumour/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/>, <https://onco.cc/key-papers/paper-gershenson-hormonal-maintenance-lgsoc-jco-2017/>, <https://onco.cc/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/> ;
  onco:pipeline <https://onco.cc/drugs/avutometinib-defactinib/>, <https://onco.cc/drugs/trametinib/> ;
  onco:standardOfCare <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/avutometinib-defactinib/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/letrozole/> .